Patrick Magahis, MD (@PatrickMagahis) profile picture

Resident @BrighamMedRes | MD @WeillCornell | AB @Harvard | Interests: gastroenterology, advanced endoscopy, EndoHepatology

Joined May 2024
Photo by Patrick Magahis, MD (@PatrickMagahis)Photo by Patrick Magahis, MD (@PatrickMagahis)
Incredibly grateful to have matched at @BrighamMedRes for Internal Medicine residency! Excited to be heading back to Boston for this next step in my training. Everything owed to my family and mentors at @WeillCornell + @MSKCancerCenter for their unconditional support. #Match2025
1
1
24
3,756
Congratulations to @PatrickMagahis, @ThomasWangMD and Marvin Ryou on this publication. Grateful to be part of this international expert consensus team. So great to see how far EUS guided coil injection therapy for the treatment of gastric varices has come over the past 10 years. @GIE_Journal @ASGEendoscopy giejournal.org/article/S0016…
1
1
7
868
Patrick Magahis, MD retweeted
Out now in @EndoscopyJrnl: a cost-effectiveness analysis of EUS-CDS with LAMS vs ERCP-BD with SEMS for primary palliation of malignant distal biliary obstruction. Markov model, US payer perspective, 1yr horizon. ICER $47,711/QALY. Cost-effective when CBD >15 mm. @PatrickMagahis
EUS-CDS vs. ERCP-BD for primary palliation of malignant distal biliary obstruction: a cost–effectiveness modeling analysis Find the article at: doi.org/10.1055/a-2837-1405 Patrick T. Magahis et al. #Endoscopy #Gastroenterology @ESGE_news @PatrickMagahis @ReemSharaiha
1
8
967
Happy to share our newest paper comparing #EUS vs #ERCP for #MDBO: 💰EUS cost-effective over ERCP (ICER $47k) ✅ Driven by ⬇️ initial cost (despite LAMS), ⬇️ reintervention rates, ⬇️ pancreatitis, ⬆️ technical success. 📊 Robust on sensitivity analyses, hospital-level analysis
EUS-CDS vs. ERCP-BD for primary palliation of malignant distal biliary obstruction: a cost–effectiveness modeling analysis Find the article at: doi.org/10.1055/a-2837-1405 Patrick T. Magahis et al. #Endoscopy #Gastroenterology @ESGE_news @PatrickMagahis @ReemSharaiha
1
1
3
330
🤔 Anatomy, expertise, patient risk factors should still drive drainage modality 💭 RCTs comparing EUS vs ERCP in all comers with MDBO critically needed 🏋️ Expanding therapeutic EUS training/accessibility is essential Thank you to my mentors @ReemSharaiha and #SriHariMahadev!
1
50
Thank you @ASGEendoscopy and @DDWMeeting for allowing us to present our work on developing and validating an EUS liver model for training in endohepatology! #DDW2026
6
28
2,262
Patrick Magahis, MD retweeted
Magahis et al compare "Outcomes of endoscopic ultrasound–guided liver biopsy using 22-gauge versus 19-gauge needles with a novel hydrostatic sampling technique." giejournal.org/article/S0016… #GITwitter @PatrickMagahis @ReemSharaiha @MarkHanscomMD
5
13
1,368
Patrick Magahis, MD retweeted
Drs Patrick T. Magahis and SriHari Mahadev discuss “Outcomes of endoscopic ultrasound–guided liver biopsy using 22-gauge versus 19-gauge needles with a novel hydrostatic sampling technique." youtu.be/cFEn4tbjCuI #GITwitter @PatrickMagahis @ReemSharaiha @MarkHanscomMD
4
13
1,120
Patrick Magahis, MD retweeted
Online now in GIE’s Articles in Press: "Outcomes of EUS-guided liver biopsy using 22-gauge versus 19-gauge needles with a novel hydrostatic sampling technique" by Patrick T. Magahis et al. giejournal.org/article/S0016… #GITwitter @PatrickMagahis @MarkHanscomMD @ReemSharaiha
1
2
8
1,282
Happy to share our recent @JNCCN study on #Cdiff infection in patients on #immunotherapy p/w diarrhea: 👉Common (18%) 👉⬆️G3-4 diarrhea but antibiotic tx alone sufficient for most 👉24% required steroids for concomitant immune-related enterocolitis (1/2) doi.org/10.6004/jnccn.2024.7…
1
1
1
1
3,600
🔑 Prompt CDI testing for all ➡️ if +, abx + close f/up ➡️ if persistent sx, endoscopy + consider steroids for concomitant irEC Thank you to my mentor and study PI @DavidFaleckMD + all our @MSKCancerCenter co-authors @MLaszkowskaMD @DeepikaSatishMD @mini_kamboj @EBabady! (2/2)
2
271
Patrick Magahis, MD retweeted
55M w/ UC x30y. Prior 5-ASA, 6MP. On IFX 5 mg/kg q8w x5y. Mild UC sx before infusions. 🔦Last scope 1y ago: Mayo 0. Now FCP 141, IFX level 3. New dx: metastatic melanoma → onc is starting nivolumab. What do you recommend for his UC?
17%Stop IFX, monitor on Nivo
37%⬆️IFX 5mg/kg q4wks+Nivo
5%Stop IFX, start Upa+Nivo
41%Stop IFX, start VDZ+Nivo
87 votes • Final results
4
13
15
2,818
So excited for this all-star intern crew to join us in June!! Huge congratulations on a fantastic and well-deserved #match2025! 🎉
3
16
7
107
38,313
Patrick Magahis, MD retweeted
Congratulations to @PatrickMagahis @AnkitChhoda and the rest of the team for their recent publication in ACG on the risk of pancreatitis after EUS-FNA! 🔑 The pooled risk of pancreatitis was 1.4% after EUS-FNA, most cases of which (67%) were mild. journals.lww.com/ajg/fulltex…
1
4
404
Here’s a closer look at recent #JITC article “Open-capsule budesonide for the treatment of immune-related enteritis from checkpoint inhibitors” by @PatrickMagahis & @DavidFaleckMD from @WeillCornell & @MSKCancerCenter. 1/11
1
2
4
759
Patrick Magahis, MD retweeted
Happy to share our experience using open capsule budesonide for successful treatment of immune-related enteritis. Grateful for my fantastic team @MSKCancerCenter who help treat these pts and made this study possible and ⭐️ med student @PatrickMagahis for putting this together.
New #JITC article: Open-capsule budesonide for the treatment of immune-related enteritis from checkpoint inhibitors bit.ly/4daLo9Z @PatrickMagahis @DavidFaleckMD
2
10
3,984
New #JITC article: Open-capsule budesonide for the treatment of immune-related enteritis from checkpoint inhibitors bit.ly/4daLo9Z @PatrickMagahis @DavidFaleckMD
1
1
2
4,783